German medical distribution company Memax has been appointed as distributor for keragelT®, the advanced wound care product developed by Keraplast using its proprietary Replicine™ Functional Keratin® technology. Dr Clive Marsh, Wound Care Development Manager for Keraplast, said “We have been working for several years with specialist clinical groups and the international DEBRA organization to establish keragelT® as the best wound management option for patients living with epidermolysis bullosa. This includes groups in Germany and Austria as well as the UK and many Scandinavian countries. As more expert groups take on keragelT® as an important wound management tool, it is essential to be able to get keragelT® to patients in a practical and efficient way. We are very excited about joining with Memax to help this happen for the families in Germany and Austria.” Dr Rob Kelly, Interim Chief Executive of Keraplast added “To make a difference in the management of EB our ground breaking keragelT® product has to be proven as effective in the hands Doctors, Nurses and the families dealing with wound care every day. In addition it has to be easily accessible and where possible covered by national reimbursement or insurance programmes. All these factors have come together in the US, UK, Australasia and several other countries. With partnership with Memax we are confident the factors will align quickly for Germany also.”
Joachim Brinkmeir, CEO of Memax said “keragelT® is a highly innovative approach to epidermolysis bullosa wound management and is backed by a high standard of peer review data. This is very consistent with the high performance products that Memax has built a strong reputation on and we are excited to now be offering this to the clinical community in Germany.